Immunological Data Discovery Index
Immunological Data Discovery Index
| authorizations: |
registration not required
|
| accessURL: |
http://www.iedb.org/reference/1025270 |
| landingPage: |
http://www.iedb.org/assay/1962872 |
| type: |
Literature
|
| publicationVenue: |
Alzheimers Dement
|
| dates: |
2012
|
| study type: | b cell assays |
| subject species: | Homo sapiens |
| fullName: |
Martin Farlow
Steven E Arnold
Christopher H van Dyck
Paul S Aisen
B Joy Snider
Anton P Porsteinsson
Stuart Friedrich
Robert A Dean
Celedon Gonzales
Gopalan Sethuraman
Ronald B DeMattos
Richard Mohs
Steven M Paul
Eric R Siemers
|
| method: |
in vivo assay
|
| name: |
Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
|
| description: |
Treatment with epitope-specific antibody did not improve Alzheimer disease measured by cognitive assessment. Antibody administration was well tolerated with doses up to 400 mg weekly. The Alzheimer’s Disease Assessment Scale–cognitive portion was unchanged after the 12-week antibody administration. The dose dependent increase in unbound CSF Ab1–42 suggests that this epitope-specific mAb may shift Ab equilibria sufficiently to mobilize Ab1–42 from amyloid plaques. For patients taking 400 mg weekly, antibody treatment decreased unbound Ab1–40 in CSF, but increased unbound Ab1–42 in CSF in a dose-dependent manner.
|
| name: |
iedb
|
| homePage: |
http://www.iedb.org |
